Financial Documents

There are "ups" and "downs" in practically every business and stock. Although there are no guarantees about the stock market or ReGen stock, before you invest in any security, you can help protect yourself by being an educated investor. If you are interested in ReGen stock (OTC: RGBI), we recommend that, at a minimum, you read our latest annual report and 10-K, 10-Q and 8-K reports to the Securities Exchange Commission (SEC) over the past year.  ReGen's recent proxy statements for shareholder meetings also contain important information. It is advisable to learn more about us and our industry through a variety of public materials.

ReGen's recent annual reports, 10-K, 10-Q and 8-K reports and other materials are accessible through this web site. Reports filed with the SEC are available through its web site at www.sec.gov. You can also visit the SEC at its Washington or various regional offices for the same information.

To view a financial document, click on the document name.  To save the document to your desktop, right click and select "Save Target As..".

Financial documents are viewable in Acrobat format.  You must have version 3.01 or higher of the Adobe Acrobat Reader to view them. To obtain this latest version, click here.

Annual Reports on Form 10-K:
Form 10-K for fiscal year ended December 31, 2007
Form 10-K for fiscal year ended December 31, 2006
Form 10-K/A for fiscal year ended December 31, 2005
Form 10-K for fiscal year ended December 31, 2004
Form 10-K/A for fiscal year ended December 31, 2003
Form 10-K/A for fiscal year ended December 31, 2002
Form 10-K/A for fiscal year ended December 31, 2001 

Quarterly Reports on Form 10-Q
Form 10-Q for the quarter ended September 30, 2008
Form 10-Q for the quarter ended June 30, 2008
Form 10-Q for the quarter ended March 31, 2008
Form 10-Q for the quarter ended September 30, 2007
Form 10-Q for the quarter ended June 30, 2007
Form 10-Q for the quarter ended March 31, 2007
Form 10-Q for the quarter ended September 30, 2006
Form 10-Q/A for the quarter ended June 30, 2006
Form 10-Q/A for the quarter ended March 31, 2006
Form 10-Q for the quarter ended September 30, 2005
Form 10-Q for the quarter ended June 30, 2005
Form 10-Q for the quarter ended March 31, 2005
Form 10-Q for the quarter ended September 30, 2004
Form 10-Q for the quarter ended June 30, 2004
Form 10-Q/A for the quarter ended March 31, 2004
Form 10-Q/A for the quarter ended September 30, 2003
Form 10-Q for the quarter ended June 30, 2003
Form 10-Q for the quarter ended March 31, 2003
Form 10-Q for the quarter ended September 30, 2002
Form 10-Q/A for the quarter ended June 30, 2002
Form 10-Q for the quarter ended March 31, 2002

Current Reports on Form 8-K
Form 8-K dated July 30, 2008
Form 8-K dated April 5, 2007
Form 8-K dated April 3, 2007
Form 8-K dated March 7, 2007
Form 8-K/A dated January 8, 2007
Form 8-K dated December 6, 2006
Form 8-K FDA dated November 13, 2006
Form 8-K Financial Restatement dated November 13, 2006
Form 8-K dated January 3, 2006
Form 8-K dated October 24, 2005
Form 8-K dated September 23, 2005
Form 8-K dated September 21, 2005
Form 8-K dated July 14, 2005
Form 8-K dated May 26, 2005 (2)
Form 8-K dated May 26, 2005
Form 8-K dated May 25, 2005
Form 8-K dated May 17, 2005

Definitive Proxy Statements
Proxy Statement on Schedule 14A dated April 21, 2008
Proxy Statement on Schedule 14A dated April 25, 2007
Proxy Statement on Schedule 14A dated April 18, 2006
Proxy Statement on Schedule 14A dated April 18, 2005
Proxy Statement on Schedule 14A dated April 29, 2004
Proxy Statement on Schedule 14A dated April 16, 2003
Proxy Statement on Schedule 14A dated November 6, 2002

Resale Prospectus
Amendment to Terminate dated May 13, 2008
Prospectus supplement dated November 9, 2007
Prospectus supplement dated August 14, 2007
Prospectus Effective with the SEC June 1, 2007 

The Menaflex™ (CMI) collagen scaffold is not cleared for sale in the U.S. and the Company makes no claim regarding its safety or efficacy for the U.S. market.